

**Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial**

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators.

Lancet

2022; 399(10336):1718-1729

**ARTICLE IDENTIFIERS**

DOI: 10.1016/S0140-6736(22)00562-1

PMID: 35367007

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: sf 82002015

pISSN: 0140-6736

eISSN: 1474-547X

OCLC ID: 01755507

CONS ID: not available

US National Library of Medicine ID: 2985213R

This article was identified from a query of the SafetyLit database.